Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.

  • 0 views
  • 15 Mar, 2022
  • 1 location
Multi Cohort Study of Tazemetostat in Combination With Various Treatments For R/R Hematologic Malignancies

This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective

  • 0 views
  • 10 Mar, 2022
  • 1 location
Study in Subjects With Relapsed/Refractory Follicular Lymphoma

designed to evaluate the efficacy and safety of tazemetostat in combination with lenalidomide and rituximab (R2) in subjects with relapsed or refractory (R/R) follicular lymphoma (FL), who have completed

  • 2 views
  • 15 Jul, 2022
  • 105 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

nitrosourea
tumor markers
hodgkin's disease
neutrophil count
neulasta
  • 1032 views
  • 25 Jul, 2022
  • 106 locations
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination

  • 0 views
  • 25 Jul, 2022
  • 2 locations
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

, and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in subjects with advanced epithelioid sarcoma (ES). This study will be conducted in 2 parts.

  • 0 views
  • 21 Mar, 2022
  • 9 locations
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses have also been

  • 0 views
  • 21 Mar, 2022
  • 1 location
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

This phase I/II trial studies the side effects and best dose of tazemetostat and how well it works when given together with pembrolizumab in treating patients with urothelial carcinoma that has

  • 44 views
  • 27 Jul, 2022
  • 23 locations
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP)

Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21. Phase II of the study is designed to

cyclophosphamide
neutrophil count
avid
follicular lymphoma
bone marrow procedure
  • 10 views
  • 27 Jan, 2022
  • 31 locations
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment

refractory follicular lymphoma
cancer
gilbert's syndrome
neutrophil count
platelet count
  • 0 views
  • 18 Apr, 2022
  • 17 locations